Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (101-110 of 217) with videos related to

Pageof 22
Sort By:
Bulletin Du Cancer|December 16, 2025
Therapeutic advances and molecular insights in low-grade serous ovarian carcinomaRayan Kabirian, Thomas Gaillard, Diana Bello-Roufai, et al.
The Journal of Pathology. Clinical Research|July 28, 2023
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 testClaire Jh Kramer, Alba Llop-Guevara, Elisa Yaniz-Galende, et al.
European Journal of Cancer (Oxford, England : 1990)|August 29, 2017
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicineLaetitia Nebot-Bral, David Brandao, Loic Verlingue, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2020
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancerAlexandra Leary, Catherine Genestie, Félix Blanc-Durand, et al.
Annals of the Rheumatic Diseases|June 11, 2017
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentRakiba Belkhir, Sébastien Le Burel, Laetitia Dunogeant, et al.
Biomarker Research|October 20, 2023
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patientsMaria Kfoury, Reda El Hazzaz, Claire Sanson, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Bulletin Du Cancer|January 30, 2026
[Recommendations for clinical practice Nice-Saint Paul de Vence 2024-2025: Management of advanced/relapsing endometrial cancer]Lauriane Eberst, Corinne Jeanne, Guillaume Bataillon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)Alexandra Leary, Abigail Evans, Stephen R D Johnston, et al.
Cancer|June 2, 2024
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancerFélix Blanc-Durand, Geraldine M Camilleri, Arnaud Bayle, et al.
Pageof 22

Showing results (101-110 of 217) with videos related to

Sort By:
Pageof 22
Bulletin Du Cancer|December 16, 2025
Therapeutic advances and molecular insights in low-grade serous ovarian carcinomaRayan Kabirian, Thomas Gaillard, Diana Bello-Roufai, et al.
The Journal of Pathology. Clinical Research|July 28, 2023
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 testClaire Jh Kramer, Alba Llop-Guevara, Elisa Yaniz-Galende, et al.
European Journal of Cancer (Oxford, England : 1990)|August 29, 2017
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicineLaetitia Nebot-Bral, David Brandao, Loic Verlingue, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2020
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancerAlexandra Leary, Catherine Genestie, Félix Blanc-Durand, et al.
Annals of the Rheumatic Diseases|June 11, 2017
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentRakiba Belkhir, Sébastien Le Burel, Laetitia Dunogeant, et al.
Biomarker Research|October 20, 2023
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patientsMaria Kfoury, Reda El Hazzaz, Claire Sanson, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Bulletin Du Cancer|January 30, 2026
[Recommendations for clinical practice Nice-Saint Paul de Vence 2024-2025: Management of advanced/relapsing endometrial cancer]Lauriane Eberst, Corinne Jeanne, Guillaume Bataillon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)Alexandra Leary, Abigail Evans, Stephen R D Johnston, et al.
Cancer|June 2, 2024
Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancerFélix Blanc-Durand, Geraldine M Camilleri, Arnaud Bayle, et al.
Pageof 22